Under construction – not a live service

Skip to content

Frontlight Research

Institution

Asan Medical Center

Seoul, South KoreaWebsite

Also known as: 서울아산병원 · AMC

640running trials
328closed trials
3researchers
49,863publications (OpenAlex)

Researchers

Running trials

Not yet recruiting
A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)
NCT07915219· Phase 3· Boehringer Ingelheim· Source
Not yet recruiting
PREventive Invasive Strategy for Obstructive Coronary Artery Disease With Vulnerable Plaque Evaluated by CoroNary Computed Tomography Angiography-2
NCT07569692· Duk-Woo Park, MD· Source
Not yet recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk
NCT07900633· Phase 3· Eli Lilly and Company· Source
Not yet recruiting
Safety and Efficacy of Autologous Natural Killer Cell Therapy (CHANK-101) in Patients With Recurrent Glioblastoma
NCT07831161· Dong-A University Hospital· Source
Not yet recruiting
A Study to Test Whether BI 3810477 Helps People With Idiopathic Pulmonary Fibrosis When Taken With or Without Standard Treatment
NCT07926321· Phase 2· Boehringer Ingelheim· Source
Not yet recruiting
A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or Both
NCT07931599· Phase 3· Novo Nordisk A/S· Source
Not yet recruiting
Hybrid Parasternal Intercostal Plane Block Versus No Block for Postoperative Analgesia After Cardiac Surgery Via Median Sternotomy
NCT07934290· Seo-hee Lee· Source
Not yet recruiting
Zastaprazan for the prEvention of Upper GI Bleeding in Ischemic Stroke
NCT07730840· Phase 3· Asan Medical Center· Source
Not yet recruiting
Predicting Endocrine Resistance Using Molecular Imaging and Liquid Biopsy in Metastatic Breast Cancer
NCT07867925· Asan Medical Center· Source
Recruiting
GI-102 (CD80-IgG4 Fc-IL2v3) in Combination With Pasritamig in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) (JET-201)
NCT07871435· Phase 1/2· GI Innovation, Inc.· Source
Recruiting
Noninferiority Trial Of Sirolimus With Ascorbic Acid Versus Everolimus in All-comers
NCT07566091· Jung-min Ahn· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
NCT07541170· Phase 3· Hoffmann-La Roche· Source
Recruiting
Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)
NCT07817875· Phase 3· Eli Lilly and Company· Source
Recruiting
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
NCT07701941· Phase 1/2· Daiichi Sankyo· Source
Recruiting
Safety and Efficacy of NDTx-03 in Children and Adolescents With ASD or SCD
NCT07770867· Neudive Inc.· Source
Recruiting
A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum
NCT07811193· Phase 2· Vividion Therapeutics, Inc.· Source
Recruiting
A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
NCT07665450· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
NCT07623200· Phase 3· Incyte Corporation· Source
Recruiting
A Phase 1 Study of ATORM-C in Patients With Crohn's Disease
NCT07822087· Phase 1· ORGANOIDSCIENCES LTD.· Source
Recruiting
SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors
NCT07812805· Phase 1· SK Life Science, Inc.· Source
Recruiting
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
NCT07775300· Phase 3· Eli Lilly and Company· Source
Recruiting
A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT07759245· Phase 2· Eli Lilly and Company· Source
Not yet recruiting
Functional And STructural Assesment of the Heart by Artificial Intelligence-enabled Electrocardiogram for the Management of Atrial Fibrillation
NCT07486739· Seoul National University Hospital· Source
Recruiting
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
NCT07492680· Phase 2· Bristol-Myers Squibb· Source
Recruiting
Treatment Patterns and Survival Outcomes in High-Grade Osteosarcoma: A Multicenter Retrospective Study
NCT07878364· MedPacto, Inc.· Source
Recruiting
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
NCT07544654· Phase 3· Boehringer Ingelheim· Source
Not yet recruiting
Evaluation of an Electric Stimulator for Medical Use by Personal (LRTPM1) for Visual Function in Early to Intermediate Dry Age-Related Macular Degeneration
NCT07700147· Nu Eyne Co., Ltd.· Source
Recruiting
A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis
NCT07516951· Phase 2· Chiesi Farmaceutici S.p.A.· Source
Not yet recruiting
Long Term Cohort Study of Adding Ovarian Function Suppression to Tamoxifen in Young Women
NCT07735897· MedicalExcellence· Source
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
NCT07581002· Phase 2/3· AbbVie· Source
Recruiting
Evaluate the Efficacy of Faricimab in Patients With Neovascular Age-related Macular Degeneration
NCT07367282· Phase 4· Junyeop Lee· Source
Recruiting
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
NCT07555938· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes
NCT07668388· Phase 2· Novo Nordisk A/S· Source
Recruiting
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
NCT07554339· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1
NCT07563881· Phase 3· Rapport Therapeutics Inc.· Source
Recruiting
Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab
NCT07486817· Phase 2· Boehringer Ingelheim· Source
Recruiting
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT07518186· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
NCT07101328· Phase 1· Eli Lilly and Company· Source
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07577856· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
NCT07525206· Phase 3· AbbVie· Source
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
NCT07577843· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
NCT07413939· Phase 2/3· Hoffmann-La Roche· Source
Recruiting
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
NCT07393282· Phase 3· Regeneron Pharmaceuticals· Source
Recruiting
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer
NCT07527858· Phase 2· Gilead Sciences· Source
Recruiting
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
NCT07567001· Phase 3· Novo Nordisk A/S· Source
Recruiting
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
NCT07549412· Phase 3· EMD Serono Research & Development Institute, Inc.· Source
Recruiting
Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)
NCT07318597· Phase 2· Regeneron Pharmaceuticals· Source
Recruiting
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
NCT07513376· Phase 3· Merck Sharp & Dohme LLC· Source
Not yet recruiting
Efficacy and Safety of a Theta Burst Stimulation Protocol of Repetitive Transcranial Magnetic Stimulation in Treatment-Resistant Depression
NCT07529574· Jung-Sun Lee· Source
Recruiting
LEXURE for Post-Stroke Aphasia
NCT07570264· Nunaps Inc· Source

Showing 50 of 640.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Closed trials

Completed
The DECISION-CTO Extended 10 Y Follow-up
NCT06908499· Seung-Jung Park· Source
Withdrawn
Spesolimab Post-marketing Surveillance in Korean Patients With Flares With Generalized Pustular Psoriasis
NCT06886009· Boehringer Ingelheim· Source
Recruiting
Phase 2 Study of AHB-137 in HBeAg Negative Chronic Hepatitis B (CHB) Participants in Asia Pacific Region
NCT07370207· Phase 2· AusperBio Therapeutics Inc.· Source
Recruiting
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
NCT07214779· Phase 3· Incyte Corporation· Source
Completed
A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depression
NCT07053345· Phase 4· Janssen Korea, Ltd., Korea· Source
Completed
A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis
NCT06921759· Phase 3· Eli Lilly and Company· Source
Terminated
TIL Therapy for Patients With Advanced Solid Tumors
NCT06107894· Phase 1· NeogenTC· Source
Completed
Clinical Validity Verification on Diagnostic Assistance for Presence and Severity of Colorectal Cancer and Polyps Using Artificial Intelligence-based Medical Device Software Endoscopic Imaging Assistance
NCT07744607· Ainex Corporation· Source
Terminated
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
NCT06585488· Phase 1· BeOne Medicines· Source
Completed
A Study to Evaluate the Efficacy and Safety of Daridorexant in Participants With Insomnia Disorder
NCT07028697· Phase 3· Nxera Pharma Korea Co., Ltd.· Source
Completed
A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT06624059· Phase 3· Hoffmann-La Roche· Source
Completed
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)
NCT06664801· Phase 2· Merck Sharp & Dohme LLC· Source
Terminated
ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension
NCT06418711· Phase 3· Mannkind Corporation· Source
Completed
A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
NCT06335303· Phase 2· Boehringer Ingelheim· Source
Completed
To Evaluate the Efficacy and Safety of 'NDTx-01' in Patients With ASD or SCD
NCT06446193· Neudive Inc.· Source
Terminated
A Study to Investigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in EGFRm NSCLC Patients
NCT06186076· Phase 1/2· Therapex Co., Ltd· Source
Completed
Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer
NCT06490328· Phase 3· Dongkook Pharmaceutical Co., Ltd.· Source
Completed
A Trial to Learn if Receiving ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk Factor
NCT06024408· Phase 1· Regeneron Pharmaceuticals· Source
Completed
A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis
NCT06280716· Phase 3· Eli Lilly and Company· Source
Completed
A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe Atopic Dermatitis
NCT06224192· Phase 3· Amgen· Source
Completed
A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes
NCT06326047· Phase 2· Novo Nordisk A/S· Source
Completed
A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NCT06131398· Phase 1· Amgen· Source
Completed
A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)
NCT06196879· Phase 2· Upstream Bio Inc.· Source
Completed
A Phase 1b/2a, Study Evaluating the Safety, PK/PD and Efficacy of NS101 in Healthy Volunteers and SSNHL Patients
NCT06249919· Phase 1/2· Neuracle Science Co., LTD.· Source
Terminated
A Study of hSTC810 in Combination With Paclitaxel in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer
NCT06016270· Phase 1/2· STCube, Inc.· Source
Completed
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration
NCT06116890· Phase 2· Kyowa Kirin Co., Ltd.· Source
Completed
Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer
NCT05954871· Phase 1· Genentech, Inc.· Source
Completed
Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
NCT05934526· Phase 3· GB002, Inc.· Source
Completed
A Study to Learn About Zavegepant as the Acute Treatment of Migraine in Asian Adults
NCT05989048· Phase 3· Pfizer· Source
Completed
Levels of Inflammation in People With Cardiovascular Disease (POSEIDON)
NCT06122961· Novo Nordisk A/S· Source
Terminated
Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
NCT06068868· Phase 1· AbbVie· Source
Recruiting
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
NCT05696626· Phase 3· LeonaBio· Source
Completed
MRI-based Artificial Intelligence Software (NNS-SOT) for Onset Time Estimation in Lesion With Acute Ischemic Stroke
NCT06160726· Nunaps Inc· Source
Recruiting
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
NCT06084936· Phase 3· Hoffmann-La Roche· Source
Recruiting
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
NCT05882058· Phase 2· Boehringer Ingelheim· Source
Completed
A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06049017· Phase 2· Janssen Research & Development, LLC· Source
Completed
A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010
NCT05867121· Phase 1· Genentech, Inc.· Source
Terminated
GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer
NCT05998447· Phase 2· Genome & Company· Source
Completed
Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)
NCT05882734· Phase 1/2· EMD Serono Research & Development Institute, Inc.· Source
Completed
A Study to Evaluate the Efficacy and Safety of AST-001 in ASD Children
NCT06333964· Phase 3· Astrogen, Inc.· Source
Completed
A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids
NCT05952856· Phase 3· Merck Sharp & Dohme LLC· Source
Completed
A First-in-human Study to Learn How Safe the Study Treatment BAY2862789 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid Tumors
NCT05858164· Phase 1· Bayer· Source
Terminated
The Study for Evaluate of Safety and Efficacy of Vein of Marshall RF Ablation
NCT05854238· Tau-MEDICAL Co., Ltd.· Source
Completed
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma
NCT05909904· Phase 2· BeiGene· Source
Completed
A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors
NCT05975073· Phase 1/2· Amgen· Source
Completed
A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma
NCT05907122· Phase 3· Amgen· Source
Completed
Study to Assess Safety and Tolerability of PMC-403 in Subjects With Neovascular Age-related Macular Degeneration
NCT05953012· Phase 1· PharmAbcine· Source
Completed
A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
NCT05852691· Phase 2· Hoffmann-La Roche· Source
Completed
Arrhythmia Detection With MEMO Patch Plus in Patients With Acute Heart Failure
NCT07792772· HUINNO Co., Ltd· Source
Completed
Effects of Hepatic Fibrosis on Hepatic Steatosis Using the Ultrasound Attenuation Imaging in Chronic Hepatitis B
NCT05871749· So Yeon Kim· Source

Showing 50 of 328.

Registry name variants (153)

Trial registries list this institution under these names. Each row is one registry entry: its address and the trials registered under it.

Asan Medical Center
Seoul, Seoul 05505
736 trials
Asan Medical Center - PPDS
Seoul, 05505
18 trials
Asan Medical Center - Oncology
Seoul, 5505
15 trials
Asan Medical Center
SongpaGu, Seoul Teugbyeolsi 05505
13 trials
Asan Medical Center (AMC)
Seoul, 05505
9 trials
Asan Medical Center, University of Ulsan College of Medicine
Seoul, 05505
9 trials
Asan Medical Centre
Seoul, 05505
7 trials
Seoul ASAN Medical Center
Seoul, 05505
6 trials
Asan Medical Center
Songpa-gu, 5505
5 trials
Asan Medical Center_Endocrinology
Seoul, 05505
3 trials
- NCT07931599A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or Both
  Contact: Novo Nordisk
- NCT07668388A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes
  Contact: Novo Nordisk
- NCT07533175AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
Asan Medical Center (Site 3004)
Seoul, 05505
3 trials
- NCT06492291Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension
- NCT06008756Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
- NCT05952856A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids
Asan Medical Center-Department of Oncology (Site 3901)
Seoul, 05505
2 trials
- NCT05845814A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)
- NCT05319730A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
  Contact: Study Coordinator
Asan Medical Center (Site 1303)
Seoul, 05505
2 trials
- NCT06925750A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)
- NCT06664801A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)
Asan Medical Center (Site 1803)
Seoul, 05505
2 trials
- NCT06966700A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
  Contact: Study Coordinator
- NCT04776148Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)
Asan Medical Center (Site 2402)
Seoul, 05505
2 trials
- NCT04895358Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
- NCT03740165Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)
Asan Medical Center (Site 2901)
Seoul, 05505
2 trials
- NCT07489495A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
  Contact: Study Coordinator
- NCT07405151A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
  Contact: Study Coordinator
Asan Medical Center, University of Ulsan
Seoul
2 trials
- NCT06616766A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946
  Contact: Dae Ho Lee
- NCT06247280Korean Registry of Non-Small Cell Lung Cancer Patients with EGFR Mutation
Asan Medical Center, Univ. of Ulsan
Seoul, 05505
2 trials
- NCT06787612Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
  Contact: Clinical Trials Administrator
- NCT03564340Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
  Contact: Clinical Trials Administrator
University of Ulsan College of Medicine - Asan Medical Center (AMC)
Seoul, 05505
2 trials
- NCT05359861Trial of Atezolizumab and Bevacizumab With CHS-388 or Placebo in Patients With Hepatocellular Carcinoma
- NCT04646005Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy
4100018 - Asan Medical Center
Seoul, 05505
1 trial
- NCT03473223Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome
Asan Medical Center
Songpa-dong, Seoul 05505
1 trial
- NCT07284459Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
  Contact: Nikki Nepomuceno
Asan Medical Center (AMC) - Site #111
Seoul, Seoul Teugbyeoisi 18450
1 trial
- NCT05248646Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)
Asan Medical Center, Asian Cacer Center
Seoul
1 trial
- NCT04459715A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)
Asan Medical Center_Cardiology
Seoul, 05505
1 trial
- NCT07567001A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
  Contact: Novo Nordisk
Asan Medical Center / Clinical Trial Center
Seoul, 138-736
1 trial
- NCT04225715A Trial To Evaluate The Efficacy And Safety Of Multiple Combination Therapies In Participants With Chronic Hepatitis B
Asan Medical Center, Department of Oncology
Seoul, 05505
1 trial
- NCT04862780(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
Asan Medical Center-Department of Oncology (Site 0405)
Seoul, 05505
1 trial
- NCT06077760A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
Asan Medical Center-Department of Oncology (Site 1103)
Seoul, 05505
1 trial
- NCT04924101Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)
Asan Medical Center-Department of Oncology (Site 1105)
Seoul, 05505
1 trial
- NCT04895722Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).
Asan Medical Center-Department of Oncology (Site 1300)
Seoul, 05505
1 trial
- NCT04704219Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)
Asan Medical Center-Department of Oncology (Site 1703)
Seoul, 05505
1 trial
- NCT05508867A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)
Asan Medical Center-Department of Oncology (Site 1901)
Seoul, 05505
1 trial
- NCT05342636A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)
Asan Medical Center-Department of Oncology (Site 2352)
Seoul, 05505
1 trial
- NCT06312176A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
  Contact: Toll Free Number
Asan Medical Center-Department of Oncology (Site 3103)
Seoul, 05505
1 trial
- NCT06393374Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
  Contact: Study Coordinator
Asan Medical Center-Department of Oncology (Site 3501)
Seoul, 05505
1 trial
- NCT06356311A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
Asan Medical Center-Department of Oncology (Site 4901)
Seoul, 05505
1 trial
- NCT06483334A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)
Asan Medical Center-Department of Oncology (Site 5901)
Seoul, 05505
1 trial
- NCT06469944Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
  Contact: Study Coordinator
Asan Medical Center-Department of Oncology (Site 7901)
Seoul, 05505
1 trial
- NCT06445972Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
  Contact: Study Coordinator
Asan Medical Center-Division of Gynecologic Oncology, Dept. of Obstetrics & Gynecology (Site 2303)
Seoul, 05505
1 trial
- NCT05173987Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
Asan Medical Center-Division of Gynecologic Oncology, Dept. of Obstetrics & Gynecology (Site 2304)
Seoul, 05505
1 trial
- NCT05116189Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).
Asan Medical Center-Division of Gynecologic Oncology, Dept. of Obstetrics & Gynecology (Site 3401)
Seoul, 05505
1 trial
- NCT06459180A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
Asan Medical Center-Division of Gynecologic Oncology, Dept. of Obstetrics & Gynecology (Site 3501)
Seoul, 05505
1 trial
- NCT06132958Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
Asan Medical Center, Division of Oncology, Department of Internal Medicine
Seoul, 05505
1 trial
- NCT01740427A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)
Asan Medical Center /ID# 125601
Seoul, 05505
1 trial
- NCT02163694A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer
Asan Medical Center /ID# 142974
Seoul, 05505
1 trial
- NCT02629159A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
Asan Medical Center /ID# 158696
Seoul, Seoul Teugbyeolsi 05505
1 trial
- NCT03105102A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
Asan Medical Center /ID# 159155
Seoul, Seoul Teugbyeolsi 05505
1 trial
- NCT03006068A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
Asan Medical Center /ID# 204236
Seoul, Seoul Teugbyeolsi 05505
1 trial
- NCT03539536Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer
Asan Medical Center /ID# 214294
Seoul, 05505
1 trial
- NCT04169373A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis
Asan Medical Center /ID# 219054
Seoul, Seoul Teugbyeolsi 05505
1 trial
- NCT04472598Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis
Asan Medical Center /ID# 221227
Seoul, Seoul Teugbyeolsi 05505
1 trial
- NCT04401748Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
Asan Medical Center /ID# 222280
Seoul, Seoul Teugbyeolsi 05505
1 trial
- NCT04189614An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer
Asan Medical Center /ID# 225758
Seoul, Seoul Teugbyeolsi 05505
1 trial
- NCT05578976A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Asan Medical Center /ID# 228444
Seoul, Seoul Teugbyeolsi 05505
1 trial
- NCT05409066Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
Asan Medical Center /ID# 230282
Seoul, Seoul Teugbyeolsi 05505
1 trial
- NCT04807972Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis
Asan Medical Center /ID# 231886
Seoul, Seoul Teugbyeolsi 05505
1 trial
- NCT04721015Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors
Asan Medical Center /ID# 234273
Seoul, 05505
1 trial
- NCT03639194A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer
Asan Medical Center /ID# 238912
Seoul, Seoul Teugbyeolsi 05505
1 trial
- NCT04433442Study to Assess the Safety and Change in Disease Symptoms of Risankizumab (Skyrizi) in Adult Participants With Moderate to Severe Plaque Psoriasis and Psoriatic Arthritis
Asan Medical Center /ID# 240286
Seoul, Seoul Teugbyeolsi 05505
1 trial
- NCT03891446Long-term Safety and Efficacy Extension Trial of Bimatoprost SR
Asan Medical Center /ID# 242400
Seoul, Seoul Teugbyeolsi 05505
1 trial
- NCT05283720A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Asan Medical Center /ID# 242409
Seoul, Seoul Teugbyeolsi 05505
1 trial
- NCT06508658A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Asan Medical Center /ID# 245215
Seoul, Seoul Teugbyeolsi 05505
1 trial
- NCT05029882Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab
Asan Medical Center /ID# 251312
Seoul, Seoul Teugbyeolsi 05505
1 trial
- NCT04541810A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic Arthritis
Asan Medical Center /ID# 252289
Seoul, Seoul Teugbyeolsi 05505
1 trial
- NCT05005403Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Asan Medical Center /ID# 253044
Seoul, Seoul Teugbyeolsi 05505
1 trial
- NCT05822752Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)
Asan Medical Center /ID# 253955
Seoul, Seoul Teugbyeolsi 05505
1 trial
- NCT06068868Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
Asan Medical Center /ID# 254022
Seoul, Seoul Teugbyeolsi 05505
1 trial
- NCT05843643Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
Asan Medical Center /ID# 257845
Seoul, Seoul Teugbyeolsi 05505
1 trial
- NCT06107413Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab
Asan Medical Center /ID# 259255
Seoul, Seoul Teugbyeolsi 05505
1 trial
- NCT06063967A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.
Asan Medical Center /ID# 260010
Seoul, Seoul Teugbyeolsi 05505
1 trial
- NCT06191744Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
Asan Medical Center /ID# 263220
Seoul, Seoul Teugbyeolsi 05505
1 trial
- NCT05512390A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)
Asan Medical Center /ID# 264228
Seoul, Seoul Teugbyeolsi 05505
1 trial
- NCT06468228A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Asan Medical Center /ID# 266341
Seoul, Seoul Teugbyeolsi 05505
1 trial
- NCT05618028Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
Asan Medical Center /ID# 266799
Seoul, Seoul Teugbyeolsi 05505
1 trial
- NCT03821935Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors
Asan Medical Center /ID# 268717
Seoul, Seoul Teugbyeolsi 05505
1 trial
- NCT06614192A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer
Asan Medical Center /ID# 269480
Seoul, Seoul Teugbyeolsi 05505
1 trial
- NCT05445778Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
Asan Medical Center /ID# 270898
Seoul, Seoul Teugbyeolsi 05505
1 trial
- NCT06632951Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)
Asan Medical Center /ID# 272130
Seoul, Seoul Teugbyeolsi 05505
1 trial
- NCT06682988A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
Asan Medical Center /ID# 274454
Seoul, Seoul Teugbyeolsi 05505
1 trial
- NCT07023289A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
Asan Medical Center /ID# 275600
Seoul, Seoul Teugbyeolsi 05505
1 trial
- NCT07005102A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Asan Medical Center /ID# 276955
Seoul, Seoul Teugbyeolsi 05505
1 trial
- NCT07059845A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
Asan Medical Center /ID# 277371
Seoul, Seoul Teugbyeolsi 05505
1 trial
- NCT07155187A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Asan Medical Center /ID# 277603
Seoul, Seoul Teugbyeolsi 05505
1 trial
- NCT07155174A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
Asan Medical Center /ID# 279395
Seoul, Seoul Teugbyeolsi 05505
1 trial
- NCT07581002A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
Asan Medical Center /ID# 282732
Seoul, Seoul Teugbyeolsi 05505
1 trial
- NCT07525206A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
Asan Medical Center: Medical Oncology Department
Seoul
1 trial
- NCT02811861Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
Asan Medical Center - Oncology Department
Seoul, Seoul Teugbyeolsi 05505
1 trial
- NCT04423718Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye
Asan Medical Center - Pulmonology
Seoul, Seoul Teugbyeolsi 05505
1 trial
- NCT07209761A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis
  Contact: Otsuka Cell Center
ASAN Medical Center (Seoul)
Seoul, 05505
1 trial
- NCT02052778A Study of TAS-120 in Patients With Advanced Solid Tumors
Asan Medical Center (Site 0006)
Seoul, Seoul 05505
1 trial
- NCT03179436Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)
Asan Medical Center (Site 0031)
Seoul, 05505
1 trial
- NCT06686394Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
  Contact: Study Coordinator
Asan Medical Center (Site 0064)
Seoul, 05505
1 trial
- NCT05609968Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
Asan Medical Center (Site 0072)
Seoul, 05505
1 trial
- NCT03062358Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)
Asan Medical Center (Site 0076)
Seoul, 05505
1 trial
- NCT03829332Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)
Asan Medical Center (Site 0082)
Seoul, 05505
1 trial
- NCT03221426Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)
Asan Medical Center (Site 0163)
Seoul, 05505
1 trial
- NCT06428409A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
  Contact: Study Coordinator
Asan Medical Center (Site 0200)
Seoul, 05505
1 trial
- NCT04241185Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
Asan Medical Center (Site 0289)
Seoul, 05505
1 trial
- NCT04740307Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)
Asan Medical Center (Site 0300)
Seoul, 05505
1 trial
- NCT03142334Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)
Asan Medical Center (Site 0310)
Seoul, 05505
1 trial
- NCT03867084Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
Asan Medical Center (Site 0460)
Seoul, Seoul-teukbyeolsi [Seoul] 05505
1 trial
- NCT03713593Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)
Asan Medical Center (Site 0503)
Seoul, 05505
1 trial
- NCT07221474A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
  Contact: Study Coordinator
Asan Medical Center (Site 0603)
Seoul, 05505
1 trial
- NCT06079879A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
Asan Medical Center (Site 0701)
Seoul, 05505
1 trial
- NCT03425643Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
Asan Medical Center (Site 0830)
Seoul, 05505
1 trial
- NCT04003636Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)
Asan Medical Center (Site 1062)
Seoul, Seoul 05505
1 trial
- NCT04221945Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)
Asan Medical Center (Site 1102)
Seoul, 05505
1 trial
- NCT05612035Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD
Asan Medical Center (Site 1200)
Seoul, 05505
1 trial
- NCT04195750A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
Asan Medical Center (Site 1313)
Seoul, 05505
1 trial
- NCT05007106MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
Asan Medical Center (Site 1355)
Seoul, 05505
1 trial
- NCT03924856Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)
Asan Medical Center (Site 1404)
Seoul, 05505
1 trial
- NCT07227597A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
  Contact: Study Coordinator
Asan Medical Center (Site 1601)
Seoul, 05505
1 trial
- NCT03635567Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)
Asan Medical Center (Site 1602)
Seoul, 05505
1 trial
- NCT06307431A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).
Asan Medical Center (Site 1800)
Seoul, 05505
1 trial
- NCT03884101Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)
Asan Medical Center (Site 1901)
Seoul, 05505
1 trial
- NCT05562830A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
Asan Medical Center (Site 2003)
Seoul, 05505
1 trial
- NCT06843447A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).
  Contact: Study Coordinator
Asan Medical Center (Site 2102)
Seoul, 05505
1 trial
- NCT03036488Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)
Asan Medical Center (Site 2105)
Seoul, 05505
1 trial
- NCT06422143Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
  Contact: Study Coordinator
Asan Medical Center (Site 2305)
Seoul, 05505
1 trial
- NCT07318558A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
  Contact: Study Coordinator
Asan Medical Center (Site 2500)
Seoul, 05505
1 trial
- NCT07554339A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
  Contact: Study Coordinator
Asan Medical Center (Site 2501)
Seoul, 05505
1 trial
- NCT07227402A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
  Contact: Study Coordinator
Asan Medical Center (Site 2702)
Seoul, 05505
1 trial
- NCT03615326Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)
Asan Medical Center (Site 2705)
Seoul, 05505
1 trial
- NCT07060807A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
  Contact: Study Coordinator
Asan Medical Center (Site 2802)
Seoul, 05505
1 trial
- NCT03675737Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)
Asan Medical Center (Site 2904)
Seoul, 05505
1 trial
- NCT07216703A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
  Contact: Study Coordinator
Asan Medical Center (Site 3007)
Seoul, 05505
1 trial
- NCT06052059A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
Asan Medical Center (Site 3103)
Seoul, 05505
1 trial
- NCT06952504A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
  Contact: Study Coordinator
Asan Medical Center (Site 3600)
Seoul, 05505
1 trial
- NCT07431827MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
  Contact: Study Coordinator
Asan Medical Center (Site 3609)
Seoul, 05505
1 trial
- NCT06430801A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
  Contact: Study Coordinator
Asan Medical Center (Site 3801)
Seoul, 05505
1 trial
- NCT06074588Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
Asan Medical Center (Site 3803)
Seoul, 05505
1 trial
- NCT06717347A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
  Contact: Study Coordinator
Asan Medical Center (Site 3810)
Seoul, 05505
1 trial
- NCT06305754Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
Asan Medical Center (Site 4061)
Seoul, 05505
1 trial
- NCT04634877Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
Asan Medical Center (Site 4200)
Seoul, 05505
1 trial
- NCT04586231A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Asan Medical Center (Site 4203)
Seoul, 05505
1 trial
- NCT04736706A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
Asan Medical Center (Site 5205)
Seoul, 05505
1 trial
- NCT07513376A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
  Contact: Study Coordinator
Asan Medical Center (Site 5800)
Seoul, 05505
1 trial
- NCT07049926Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
  Contact: Study Coordinator
Asan Medical Center (Site 5901)
Seoul, 05505
1 trial
- NCT07232602KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
  Contact: Study Coordinator
Asan Medical Center (Site 9901)
Seoul, 05505
1 trial
- NCT06780111Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
  Contact: Study Coordinator
Asan Medical Center (Site A)
Seoul, 05505
1 trial
- NCT03776123Post-marketing Surveillance on the Safety of CabometyxTM in Korean Patients
Asan Medical Center (Site B)
Seoul, 05505
1 trial
- NCT03776123Post-marketing Surveillance on the Safety of CabometyxTM in Korean Patients
Asan Medical Center,Substudy-02
Seoul, 05505
1 trial
- NCT05633667Study of Novel Treatment Combinations in Patients With Lung Cancer
Asan Medical Center,Substudy-03
Seoul, 05505
1 trial
- NCT05633667Study of Novel Treatment Combinations in Patients With Lung Cancer
Asan Medical Center - University of Ulsan College of Medicin
Seoul, 05505
1 trial
- NCT03592472A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
  Contact: Sophia Paspal, Ph.D.
Asan Medical Center: Urology Department
Seoul
1 trial
- NCT02811861Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
Asan Medical Centre - 3103
Seoul, 05505
1 trial
- NCT05671510ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
Asan Medical Centre,Substudy-01
Seoul, 05505
1 trial
- NCT05633667Study of Novel Treatment Combinations in Patients With Lung Cancer
Cancer Center Clinical Trial, Asan Medical Center
Seoul, 05505
1 trial
- NCT03395197Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC
Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center
Seoul, 138-736
1 trial
- NCT05912972Development and Management of Registry in Patients With Gynecologic Cancer in Korea
  Contact: Jeong-Yeol Park, M.D., Ph.D.
Department of Oncology, Asan Medical Center
Seoul
1 trial
- NCT05243797Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Liver cancer center, Asan Medical Center
Seoul, Song-pa 05505
1 trial
- NCT06819566Prophylactic Endoscopic Variceal Ligation in Patients With High-risk Esophageal Varices Receiving Atezo/Bev for HCC
  Contact: Ju Hyun Shim, MD, PhD
University of Ulsan College of Medicine - Asan Medical Center
Seoul, 05505
1 trial
- NCT04209855A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression
University of Ulsan College of Medicine - Asan Medical Center (AMC) - Cardiology Department
Seoul, Seoul Teugbyeolsi 05505
1 trial
- NCT05686070A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

Conditions

Diseases this institution publishes on or runs trials for.

Institution data: ROR 03s5q0090 (CC0-1.0)Updated 12 Nov 2026

Report an error

Under construction, not live – Asan Medical Center: trials and research groups – Frontlight Research